Anticancer Potential of Hesperidin against HEp-2 Laryngeal Carcinoma Cell Line in Comparison to Doxorubicin

BACKGROUND: Doxorubicin (DOX) is a drug that frequently used to treat variety of cancers. Unfortunately, in many situations, it ineffective, and raising the dosage restricted due systemic toxicity. An important strategy minimize toxic effects above cited use co-adjuvant. A citrus flavonoid hesperidin (Hesp) has emerged as promising anticancer natural product proved be potent antioxidant agent. It suppresses cancer cell replicating by triggering apoptosis cycle arrest. AIM: The study’s goal was investigate anticarcinogenic Hesp comparison with DOX against HEp-2 laryngeal carcinoma line. MATERIALS AND METHODS: Five groups line were included, two subjected other DOX, which reference drug, addition control untreated group. Expression Bcl-2 p53 genes evaluated. Furthermore, arrest apoptotic induction assessed. RESULTS: exerted anti-proliferative cells increase time dependent manner. Gene profile analysis revealed highly statistically significant decrease anti-apoptotic expression tumor suppressor gene (p ˂ 0.01 p 0.0001, respectively) for both tested drugs. CONCLUSIONS: potential reducing viability through mechanism. could prodrug or coadjuvant treatment oral cancer.